Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2025)

Organogenesis Holdings has reported Preferred Stock Liabilities over the past 5 years, most recently at $133.8 million for Q4 2025.

  • Quarterly results put Preferred Stock Liabilities at $133.8 million for Q4 2025, up 9.29% from a year ago — trailing twelve months through Dec 2025 was $133.8 million (up 9.29% YoY), and the annual figure for FY2025 was $133.8 million, up 9.29%.
  • Preferred Stock Liabilities for Q4 2025 was $133.8 million at Organogenesis Holdings, up from $130.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for ORGO hit a ceiling of $133.8 million in Q4 2025 and a floor of $122.4 million in Q4 2024.